Department of Gynecology and Obstetrics, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic.
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic.
Sci Rep. 2022 Nov 15;12(1):19543. doi: 10.1038/s41598-022-24253-y.
In the literature on the safety of ursodeoxycholic acid (UDCA) during breastfeeding, insufficient data has been reported to date. Thus, the aim of our study was to analyze bile acid (BA) concentrations in breast milk in a cohort of patients, treated with UDCA, and with various cholestatic liver diseases. The study was carried out on a cohort of 20 patients with various cholestatic diseases. All the patients were treated with UDCA (500-1500 mg daily). Concentrations of BA, sampled on day 3 after delivery were analyzed using the GS-MS technique, and then compared to untreated women. Total BA concentrations in the breast milk of the UDCA-treated patients were equal to those of the untreated women controls (3.2 ± 1 vs. 3.2 ± 0.2 µmol/L, respectively). The UDCA concentrations in breast milk remained negligible in UDCA-treated patients (0.69 µmol/L), and in any event did not contribute to the newborn BA pool. No apparent side-effects of the maternal UDCA treatment were observed in any newborn infant, and no deterioration in postnatal development was observed during the routine 1-year follow-ups. Therapeutic administration of UDCA during lactation is safe for breastfed babies since UDCA only gets into breast milk in negligible amounts. UDCA treatment should be allowed and included into the guidelines for the therapy of cholestatic diseases in breastfeeding mothers.
在关于熊去氧胆酸（UDCA）在哺乳期安全性的文献中，目前报道的数据不足。因此，我们的研究目的是分析一组接受 UDCA 治疗的患有各种胆汁淤积性肝病的患者的母乳中胆汁酸（BA）浓度。该研究对 20 名患有各种胆汁淤积性疾病的患者进行了研究。所有患者均接受 UDCA（每日 500-1500mg）治疗。使用 GS-MS 技术分析分娩后第 3 天采集的 BA 浓度，并与未经治疗的女性进行比较。UDCA 治疗患者的母乳中总 BA 浓度与未经治疗的女性对照组相当（分别为 3.2±1 与 3.2±0.2 µmol/L）。UDCA 在母乳中的浓度在 UDCA 治疗患者中仍然微不足道（0.69 µmol/L），并且无论如何都不会增加新生儿的 BA 池。在任何新生儿中均未观察到母亲 UDCA 治疗的明显副作用，并且在常规的 1 年随访期间，未观察到新生儿发育恶化。在哺乳期给予 UDCA 治疗对母乳喂养的婴儿是安全的，因为 UDCA 只有在微不足道的量进入母乳。UDCA 治疗应被允许，并纳入母乳喂养母亲胆汁淤积性疾病治疗指南。
